1-20 of 119
Philip A. Thompson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia

Jayastu Senapati, Nicholas Short, Yesid Alvarado, Jan A. Burger, Nitin Jain, Marina Konopleva, Farhad Ravandi, Courtney D. DiNardo, Lucia Masarova, Koji Sasaki, Philip A. Thompson, Alessandra Ferrajoli, Jovitta Jacob, Ejiroghene Mayor, Anna Milton, Christopher Loiselle, Rebecca Garris, Hagop Kantarjian, Elias Jabbour
Journal: Blood
Blood (2022) 140 (Supplement 1): 3253–3255.
DOI: https://doi.org/10.1182/blood-2022-170667
Published: 2022
Journal Articles

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3 -Mutated Acute Myeloid Leukemia

Nicholas Short, Courtney D. DiNardo, Naval Daver, Walid Macaron, Musa Yilmaz, Gautam Borthakur, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Ghayas C. Issa, Koji Sasaki, Philip A. Thompson, Jan A. Burger, Abhishek Maiti, Yesid Alvarado, Monica Kwari, Ricardo Delumpa, Jennifer Thankachan, Ejiroghene Mayor, Christopher Loiselle, Anna Milton, Glenda Banks, Tapan M. Kadia, Marina Konopleva, Hagop Kantarjian, Farhad Ravandi
Journal: Blood
Blood (2022) 140 (Supplement 1): 2007–2009.
DOI: https://doi.org/10.1182/blood-2022-157210
Published: 2022
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jayastu Senapati, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev E. Estrov, Marina Konopleva, Koji Sasaki, Tapan M. Kadia, Naveen Pemmaraju, Naval Daver, Elias Jabbour, Courtney D. DiNardo, Yesid Alvarado, Musa Yilmaz, Prithviraj Bose, Maro Ohanian, Rashmi Kanagal-Shamanna, Keyur Patel, Jeffrey L. Jorgensen, Sa A Wang, Sameh Nassar, Naveen Garg, Hyunsoo Hwang, Xuemei Wang, Nichole Cruz, Ana Ayala, William Plunkett, Hagop Kantarjian, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2022) 140 (Supplement 1): 234–237.
DOI: https://doi.org/10.1182/blood-2022-170850
Published: 2022
Journal Articles

Pharmacological Profiling of Cells from Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Pirtobrutinib

Shady I. Tantawy, Burcu Aslan, Lisa S Chen, Lakesla Iles, Philip A. Thompson, Nitin Jain, William G. Wierda, Varsha Gandhi
Journal: Blood
Blood (2022) 140 (Supplement 1): 501–502.
DOI: https://doi.org/10.1182/blood-2022-171119
Published: 2022
Journal Articles

Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader

Daisy Diaz Rohena, Bailey Slawin, Janani Ravikrishnan, Chaomei Liu, Wanyi Hu, Peiyi Zhang, Philip A. Thompson, William G. Wierda, Nitin Jain, Guangrong Zheng, Daohong Zhou, Jennifer A. Woyach, Deepa Sampath
Journal: Blood
Blood (2022) 140 (Supplement 1): 497–498.
DOI: https://doi.org/10.1182/blood-2022-168345
Published: 2022
Journal Articles

Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial

Nitin Jain, Elias Jabbour, Ibrahim Aldoss, Marina Konopleva, Nicholas Short, Anthony S. Stein, Naveen Pemmaraju, Philip A. Thompson, Farhad Ravandi, Hagop Kantarjian
Journal: Blood
Blood (2022) 140 (Supplement 1): 521–522.
DOI: https://doi.org/10.1182/blood-2022-170730
Published: 2022
Journal Articles

Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies

Kelly S. Chien, Christine B. Peterson, Elliana Young, Dai Chihara, Elisabet E. Manasanch, Jeremy L. Ramdial, Philip A. Thompson
Journal: Blood
Blood (2022) 140 (Supplement 1): 10938–10939.
DOI: https://doi.org/10.1182/blood-2022-169993
Published: 2022
Journal Articles

Tolerability of Acalabrutinib after Prior Ibrutinib Treatment in Patients with CLL: Experience of a Tertiary Cancer Care Center

Adam J DiPippo, Alicia McGhie, Jenessa Lee, Philip A. Thompson, Nitin Jain, William G. Wierda, Hagop Kantarjian, Alessandra Ferrajoli
Journal: Blood
Blood (2022) 140 (Supplement 1): 4153–4155.
DOI: https://doi.org/10.1182/blood-2022-167583
Published: 2022
Journal Articles

Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma

Stephen E. Spurgeon, Matthew Mei, Paul M. Barr, Jacqueline C. Barrientos, Sven de Vos, Richard R. Furman, Krish Patel, Philip A. Thompson, Michael Y. Choi, Avyakta Kallam, Sirou Wang, Uzor C. Ogbu, Akash Nahar, Michael L. Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 6640–6641.
DOI: https://doi.org/10.1182/blood-2022-163509
Published: 2022
Journal Articles

The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study

Nicholas Short, Elias Jabbour, Farhad Ravandi, Musa Yilmaz, Tapan M. Kadia, Philip A. Thompson, Xuelin Huang, Marina Konopleva, Alessandra Ferrajoli, Nitin Jain, Koji Sasaki, Walid Macaron, Yesid Alvarado, Gautam Borthakur, Courtney D. DiNardo, Maro Ohanian, Steven M. Kornblau, Min Zhao, Monica Kwari, Jennifer Thankachan, Christopher Loiselle, Ricardo Delumpa, Rebecca Garris, Hagop Kantarjian
Journal: Blood
Blood (2022) 140 (Supplement 1): 8966–8968.
DOI: https://doi.org/10.1182/blood-2022-157358
Published: 2022
Journal Articles

Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year

Philip A. Thompson, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Christine B. Peterson, Naveen Garg, Ana Ayala, Jon A Hernandez, Tapan M. Kadia, Prithviraj Bose, Naveen Pemmaraju, Nicholas Short, William G. Wierda
Journal: Blood
Blood (2022) 140 (Supplement 1): 238–240.
DOI: https://doi.org/10.1182/blood-2022-170030
Published: 2022
Journal Articles

Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia

Tareq Abuasab, Fadi Haddad, Shehab Fareed Mohamed, Jeffrey L. Jorgensen, Sa A Wang, Philip A. Thompson, Tapan M. Kadia, Yesid Alvarado, Sherry A. Pierce, Michael J. Keating, David McCue, Hagop Kantarjian, Farhad Ravandi
Journal: Blood
Blood (2022) 140 (Supplement 1): 9385–9386.
DOI: https://doi.org/10.1182/blood-2022-165639
Published: 2022
Journal Articles

High Cell Death Rates at Start of Ibrutinib Therapy Predict for Deeper Remissions in Patients with Chronic Lymphocytic Leukemia (CLL)

Ekaterina Kim, Mariela Sivina, Alicia Vaca, Alessandra Ferrajoli, Nitin Jain, Philip A. Thompson, William G. Wierda, Dominik Wodarz, Nicholas Chiorazzi, Jan A. Burger
Journal: Blood
Blood (2022) 140 (Supplement 1): 4140–4141.
DOI: https://doi.org/10.1182/blood-2022-160238
Published: 2022
Journal Articles

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

William G. Wierda, David John Lewis, Paolo Ghia, Nirav N. Shah, Catherine C. Coombs, Chan Y. Cheah, Nicole Lamanna, Joanna M. Rhodes, Marc Hoffmann, Shuo Ma, Toby A. Eyre, Talha Munir, Manish R. Patel, Alvaro J. Alencar, Constantine S. Tam, John F. Seymour, Wojciech Jurczak, Ewa Lech-Marańda, Lindsey E. Roeker, Philip A. Thompson, Paolo B. Abada, Chunxiao Wang, Binoj Nair, Hui Liu, Donald E. Tsai, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 846–849.
DOI: https://doi.org/10.1182/blood-2022-157058
Published: 2022
Journal Articles

Early Treatment with Ofatumumab in Patients with High-Risk CLL

Sai Prasad Desikan, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Maro Ohanian, Naveen Pemmaraju, Courtney D. DiNardo, Marina Konopleva, Tapan M. Kadia, Susan O'Brien, Zeev E. Estrov, Deborah A Thomas, Jan A. Burger, Philip A. Thompson, William G. Wierda
Journal: Blood
Blood (2022) 140 (Supplement 1): 9876–9878.
DOI: https://doi.org/10.1182/blood-2022-167284
Published: 2022
Journal Articles

Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome

Clinical Trials & Observations Brief Report
Matthew S. Davids, Kerry A. Rogers, Svitlana Tyekucheva, Zixu Wang, Samantha Pazienza, Sarah K. Renner, Josie Montegaard, Udochukwu Ihuoma, Timothy Z. Lehmberg, Erin M. Parry, Catherine J. Wu, Caron A. Jacobson, David C. Fisher, Philip A. Thompson, Jennifer R. Brown
Journal: Blood
Blood (2022) 139 (5): 686–689.
DOI: https://doi.org/10.1182/blood.2021011386
Published: 2022
Includes: Supplemental data
Journal Articles

Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy

Hua-Jay J. Cherng, Raamis Khwaja, Rashmi Kanagal-Shamanna, Jan A. Burger, Philip A. Thompson, Alessandra Ferrajoli, Zeev E. Estrov, Koji Sasaki, Deepa Sampath, Guilin Tang, Xuemei Wang, Hagop Kantarjian, Michael J. Keating, William G. Wierda, Nitin Jain
Journal: Blood
Blood (2021) 138 (Supplement 1): 394.
DOI: https://doi.org/10.1182/blood-2021-146432
Published: 2021
Journal Articles

A Phase I/II Study of Venetoclax in Combination with 5-Azacytidine in Treatment-Naïve and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Alexandre Bazinet, Elias J. Jabbour, Hagop Kantarjian, Kelly S. Chien, Courtney D. DiNardo, Maro Ohanian, Naval Daver, Rashmi Kanagal-Shamanna, Tapan M. Kadia, Koichi Takahashi, Lucia Masarova, Nicholas J. Short, Yesid Alvarado, Philip A. Thompson, Guillermo Montalban-Bravo, Musa Yilmaz, Farhad Ravandi, Steven M. Kornblau, Naveen Pemmaraju, Heather Schneider, Bailey Mirabella, Kiran Naqvi, Guillermo Garcia-Manero
Journal: Blood
Blood (2021) 138 (Supplement 1): 535.
DOI: https://doi.org/10.1182/blood-2021-153086
Published: 2021
Journal Articles

Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma

Michael Wang, Matthew Mei, Paul M. Barr, Jacqueline Barrientos, Sven de Vos, Richard Furman, Krish Patel, Philip A. Thompson, Michael Choi, Avyakta Kallam, Ying Zhu, Samhita Chakraborty, Patricia Marinello, Stephen E. Spurgeon
Journal: Blood
Blood (2021) 138 (Supplement 1): 528.
DOI: https://doi.org/10.1182/blood-2021-148607
Published: 2021
Journal Articles

Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups

Abhishek Maiti, Courtney D. DiNardo, Caitlin R. Rausch, Naveen Pemmaraju, Guillermo Garcia-Manero, Maro Ohanian, Naval Daver, Ghayas C. Issa, Gautam Borthakur, Farhad Ravandi, Yesid Alvarado, Tapan M. Kadia, Elias J. Jabbour, Nicholas J. Short, Guillermo Montalban-Bravo, Nitin Jain, Steven M. Kornblau, Lucia Masarova, William G. Wierda, Koji Sasaki, Koichi Takahashi, Musa Yilmaz, Jan A. Burger, Zeev E. Estrov, Srdan Verstovsek, Michael Andreeff, Prithviraj Bose, Alessandra Ferrajoli, Philip A. Thompson, Kathryn Montalbano, Kenneth Vaughan, Carol A. Bivins, Sherry A. Pierce, Wei Qiao, Jing Ning, John S. Welch, Hagop Kantarjian, Marina Konopleva
Journal: Blood
Blood (2021) 138 (Supplement 1): 694.
DOI: https://doi.org/10.1182/blood-2021-153227
Published: 2021